Vijaya Diagnostic Centre Limited has informed the Exchange that Board of Directors at its meeting held on May 12, 2025, recommended Final Dividend of 2 per equity share.
VIJAYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vijaya Diagnostic Centre's board, at its May 12, 2025 meeting, approved audited standalone and consolidated financial results for Q4 and FY25 (year ended March 31, 2025) with an unmodified opinion from statutory auditors. The board recommended a final dividend of ₹2 per equity share (200% on the ₹1 face value), subject to shareholder approval at the upcoming AGM; the record date is yet to be announced. Mr. S. Ramachandra Reddy (currently GM-Finance, ex-Dr. Reddy's Labs and Coromandel) was appointed Interim CFO, and Mr. Lanka Sai Srinivas (ex-UnitedHealth Group and Wipro) was appointed CTO. M/s. Santhosh & Associates were re-appointed as Cost Auditors for FY25-26. Additionally, 1,91,150 ESOPs were granted at ₹815 per option (a 20% discount to the 3-month average closing price) under the VDCL ESOP Plan 2018.
The ₹2 dividend translates to a very modest yield of roughly 0.2% at the implied current market price (around ₹1,019), so it is unlikely to be a major price catalyst. The Interim CFO appointment alongside a new CTO and a sizable ESOP grant at a discounted exercise price are routine but worth monitoring for governance and dilution signals.